Israel - English - Ministry of Health

novartis israel ltd - pemetrexed as disodium - powder for concentrate for solution for infusion - pemetrexed as disodium 500 mg/vial - pemetrexed - pemetrexed sandoz in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. pemetrexed sandoz in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sandoz is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - English - Ministry of Health

novartis israel ltd - pemetrexed as disodium - powder for concentrate for solution for infusion - pemetrexed as disodium 500 mg/vial - pemetrexed - pemetrexed sandoz in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. pemetrexed sandoz in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sandoz is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Israel - English - Ministry of Health

novartis israel ltd - pemetrexed as disodium - powder for concentrate for solution for infusion - pemetrexed as disodium 100 mg/vial - pemetrexed - pemetrexed sandoz in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. pemetrexed sandoz in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sandoz is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604.05 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: mannitol; hydrochloric acid; nitrogen; sodium hydroxide - pemetrexed juno, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer pemetrexed juno in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed juno as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 120.81 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: sodium hydroxide; nitrogen; mannitol; hydrochloric acid - pemetrexed juno, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer pemetrexed juno in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed juno as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pemetrexed disodium, quantity: 1102.8 mg (equivalent: pemetrexed, qty 1000 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma pemetrexed sun, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed sun in combination with cisplatin is indicated for initial treatment of patients with locally advance or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sun as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pemetrexed disodium, quantity: 551.4 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma pemetrexed sun, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed sun in combination with cisplatin is indicated for initial treatment of patients with locally advance or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sun as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pemetrexed disodium, quantity: 110.28 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma pemetrexed sun, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed sun in combination with cisplatin is indicated for initial treatment of patients with locally advance or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sun as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pemetrexed disodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - pemetrexed disodium -